about
Multi-determinants analysis of molecular alterations for predicting clinical benefit to EGFR-targeted monoclonal antibodies in colorectal cancerReplacement of normal with mutant alleles in the genome of normal human cells unveils mutation-specific drug responsesHow PI3K-derived lipids control cell divisionWild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies.Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.BRAF V600E is a determinant of sensitivity to proteasome inhibitorsPI3K class II α controls spatially restricted endosomal PtdIns3P and Rab11 activation to promote primary cilium functionKnock-in of oncogenic Kras does not transform mouse somatic cells but triggers a transcriptional response that classifies human cancers.Targeting oncogenic serine/threonine-protein kinase BRAF in cancer cells inhibits angiogenesis and abrogates hypoxia.Measurement of PIP3 levels reveals an unexpected role for p110β in early adaptive responses to p110α-specific inhibitors in luminal breast cancer.Integrated molecular dissection of the epidermal growth factor receptor (EGFR) [corrected] oncogenic pathway to predict response to EGFR-targeted monoclonal antibodies in metastatic colorectal cancer.Targeted therapies: how personal should we go?Targeting PI3K in Cancer: Any Good News?PI3K in cancer-stroma interactions: bad in seed and ugly in soil.PI3K/AKT signaling pathway and cancer: an updated review.PI3K Signaling in Tissue Hyper-Proliferation: From Overgrowth Syndromes to Kidney Cysts.Mixed lineage kinase MLK4 is activated in colorectal cancers where it synergistically cooperates with activated RAS signaling in driving tumorigenesis.Modeling tumor progression by the sequential introduction of genetic alterations into the genome of human normal cells.Rac signal adaptation controls neutrophil mobilization from the bone marrow.Mitotic Spindle Assembly and Genomic Stability in Breast Cancer Require PI3K-C2α Scaffolding Function.Cytokinetic Abscission: Phosphoinositides and ESCRTs Direct the Final Cut.Phosphoinositide 3-Kinase Gamma Inhibition Protects from Anthracycline Cardiotoxicity and Reduces Tumor Growth.The turtle and the rabbit story in a modern (PI3)key.Signaling Pathways Regulating Redox Balance in Cancer Metabolism.Erratum to: Integrated molecular dissection of the epidermal growth factor receptor (EGFR) oncogenic pathway to predict response to EGFR-targeted monoclonal antibodies in metastatic colorectal cancerPhosphoinositides in cell proliferation and metabolismClass II PI3K Functions in Cell Biology and DiseaseTargeting PI3K signaling in cancer: Challenges and advancesThe role of metabolic adaptation to nutrient stress in pancreatic cancer
P50
Q21142734-9C33E214-D22E-417C-9C89-4337F4AA4FA6Q24658420-A25FBEA1-642E-46D3-ABFE-1FB9183428E9Q26781315-6B36F023-D24C-499B-BD60-97E0D6E28725Q27851456-5D5ECC0F-6B62-4C75-A16F-5CB10752845EQ27851465-FFC46D34-E516-4883-9D08-BB6ABB2FF266Q27851573-50F72F17-DA8C-4D11-984B-4D66A04EBEEFQ28300004-CC5AA6F2-E1DC-4AB0-9787-32977CC75613Q33701751-F16B5709-3075-4B0D-B67B-F70506588AE6Q34688930-2F79A108-D9AA-4DC7-9328-01319B2FBB92Q35751013-9425174D-E1C4-4372-AB45-93FF2F3D8BFAQ36557786-846CA348-CE60-40E1-8AC5-84B75C662BDEQ37728990-0F97683A-2743-4C69-8346-AEC8DF9D6F92Q37956110-E9C7C85B-82A0-4DAE-849E-26A74421B277Q38105322-F5F76B76-BBEF-46ED-B7F4-4341EFF0FC27Q38124762-620BF4B4-311F-4E27-A280-A289E63A5A35Q38217651-A6983BD6-F6A6-4228-AC3C-40EA0C444914Q39206695-D3E86B90-9CCA-49C8-BD6B-4DCE4AF77265Q39210312-95D24502-0D80-4927-B304-555D48F9A5D9Q39215523-97BAC8C1-1F26-40E4-93B0-E3F9D8415EE0Q42503313-D212E331-0ACD-4EDA-A995-DFB5CC9D9F49Q47583505-B1B65B83-1292-4E9A-9280-BED6D328AB4CQ48263976-F57F7322-C9E5-4397-922F-B857F50CC70EQ49953587-7DAB5D65-5708-4FA2-AF24-A5C121CE39FDQ50195436-EB0E1C34-5CB4-4B05-A547-68624A169946Q54979494-FD1A625F-4273-4A18-BC1F-BAE49358B9D7Q57280837-6F3C07D0-80DA-465A-A90F-4E21F124D6C0Q89489400-3641D2E8-C102-4661-B47E-9676A519626FQ91257671-46AEB22D-ABC3-40D0-B624-082EA4A1EEFBQ92849861-F44333D2-B120-4730-8CD6-BE27ADC5885CQ92932132-CE4A8130-27A3-459B-947C-5452D3552FBD
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Miriam Martini
@ast
Miriam Martini
@en
Miriam Martini
@es
Miriam Martini
@sl
type
label
Miriam Martini
@ast
Miriam Martini
@en
Miriam Martini
@es
Miriam Martini
@sl
prefLabel
Miriam Martini
@ast
Miriam Martini
@en
Miriam Martini
@es
Miriam Martini
@sl
P1053
K-3053-2016
P106
P1153
21743032500
P21
P2798
P31
P3829
P496
0000-0002-4262-946X